Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
By K. Flaherty, I. Puzanov, Kevin B. Kim, Antoni Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard J Lee, J. Grippo, K. Nolop and 1 more. New England Journal of Medicine, 2010
3,615 citations recorded by the source corpus.
Background The identification of somatic mutations in the gene encoding the serine–threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. Methods We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the recommended phase 2 dose). Patients received PLX4032 twice daily until they had disease progression. Pharmacokinetic analysis and tumor-response assessments were conducted in all patients. In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition. Results A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response. Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response. The estimated median progression-free survival among all patients was more than 7 months. Conclusions Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/86665a3d2c3b839dd66711b7ed9d1bc282a39531
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
- Shankar Balasubramanian
- S. Rosenberg
- Stephen Neidle
- Myles A. Brown
- X. S. Liu
- N. Restifo
- M. Dudley
- L. Hurley
In Oncology
Citations in the corpus
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma (2011, background): “Recent data from a phase I clinical trial with the specific inhibitor PLX4032 in patients with metastasized BRAF mutant malignant melanoma nourishes the hope that BRAF mutation may become a prime target of cancer therapy in the near future [10].”
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011, background): “All patients 93 20 (22) 32 (34) 52 (56) Prior treatment None 5 (5) 2 (40) 1 (20) 3 (60) IL-2 77 (83) 14 (18) 28 (36) 42 (54) Chemotherapy 40 (43) 7 (18) 16 (40) 23 (58) IFN 52 (56) 11 (21) 17 (33) 28 (54) Anti-CTLA4 11 (12) 5 (45) 2 (18) 7 (64) IL-2þ chemotherapy 37 (40) 6 (16) 16 (43) 22 (59) IL-2þ”
- Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA (2014, positive): “Non-small cell lung cancer (NSCLC) harboring EGFR and ALK mutations and melanomas harboring BRAF mutations have been shown to be highly sensitive to targeted kinase inhibition (1-3).”
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function (2014, methodology): “was measured using MitoProbe DilC1(5) Assay Kit for Flow Cytometry (Molecular Probes) according to specifications, and CCCP treatment was used for controls.”
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011, background): “Clinical trials of the potent inhibitors of V600mutant BRAF, vemurafenib (6, 7) andGSK2118436 (8, 9), show tumor shrinkage in themajority of patients with BRAF mutant metastatic melanoma.”
- Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011, background): “The most promising of these has been PLX4032, which was associated with an 80% response rate in the extension phase of a recent multicenter phase I study that included 32 patients with advanced-stage melanoma with BRAF V600E mutations.(18) On the basis of these results, a randomized phase III study ”
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011, background): “The proven effect of this approach in the recent BRAF and ALK phase 1 trials demonstrates the need for molecular stratification (44, 45).”
- Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “GSK2118436 (another ATP-competitive BRAF inhibitor), has recently shown a dramatic response rates of 70 -- 80% as single agent in metastatic melanoma patients [84,93,94].”